Teachers Advisors LLC boosted its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 6.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 42,679 shares of the biopharmaceutical company’s stock after purchasing an additional 2,500 shares during the period. Teachers Advisors LLC owned approximately 0.15% of Ocular Therapeutix worth $396,000 at the end of the most recent quarter.
A number of other large investors also recently bought and sold shares of the business. Parametric Portfolio Associates LLC grew its position in Ocular Therapeutix by 1.3% in the 1st quarter. Parametric Portfolio Associates LLC now owns 30,582 shares of the biopharmaceutical company’s stock worth $284,000 after purchasing an additional 401 shares during the period. American International Group Inc. grew its position in Ocular Therapeutix by 8.2% in the 1st quarter. American International Group Inc. now owns 11,138 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 844 shares during the period. Alps Advisors Inc. grew its position in Ocular Therapeutix by 5.9% in the 2nd quarter. Alps Advisors Inc. now owns 26,201 shares of the biopharmaceutical company’s stock worth $243,000 after purchasing an additional 1,462 shares during the period. Rhumbline Advisers grew its position in shares of Ocular Therapeutix by 22.1% during the 2nd quarter. Rhumbline Advisers now owns 27,386 shares of the biopharmaceutical company’s stock valued at $254,000 after acquiring an additional 4,958 shares during the period. Finally, Alliancebernstein L.P. grew its position in shares of Ocular Therapeutix by 52.7% during the 2nd quarter. Alliancebernstein L.P. now owns 41,700 shares of the biopharmaceutical company’s stock valued at $387,000 after acquiring an additional 14,400 shares during the period. 52.35% of the stock is owned by institutional investors and hedge funds.
A number of equities research analysts have recently issued reports on OCUL shares. ValuEngine raised shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research report on Monday, July 24th. HC Wainwright started coverage on shares of Ocular Therapeutix in a research report on Wednesday, July 26th. They set a “buy” rating and a $10.00 price objective for the company. BTIG Research reissued a “neutral” rating on shares of Ocular Therapeutix in a research report on Thursday, August 10th. Cantor Fitzgerald reissued a “buy” rating and set a $21.00 price objective on shares of Ocular Therapeutix in a research report on Monday, September 25th. Finally, Guggenheim started coverage on shares of Ocular Therapeutix in a research report on Monday, October 23rd. They set a “buy” rating and a $12.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. Ocular Therapeutix currently has a consensus rating of “Hold” and a consensus price target of $22.29.
Shares of Ocular Therapeutix, Inc. (OCUL) opened at $5.21 on Wednesday. Ocular Therapeutix, Inc. has a 1 year low of $4.70 and a 1 year high of $11.91. The company has a debt-to-equity ratio of 0.39, a quick ratio of 4.78 and a current ratio of 4.79.
Ocular Therapeutix (NASDAQ:OCUL) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.54). Ocular Therapeutix had a negative net margin of 3,241.19% and a negative return on equity of 126.31%. The company had revenue of $523.00 million for the quarter, compared to analysts’ expectations of $0.52 million. During the same quarter in the previous year, the company earned ($0.39) EPS. Ocular Therapeutix’s revenue for the quarter was up 9.6% on a year-over-year basis. sell-side analysts forecast that Ocular Therapeutix, Inc. will post -2.35 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://sportsperspectives.com/2017/11/15/ocular-therapeutix-inc-ocul-shares-bought-by-teachers-advisors-llc.html.
Ocular Therapeutix Profile
Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.
Want to see what other hedge funds are holding OCUL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ocular Therapeutix, Inc. (NASDAQ:OCUL).
Receive News & Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.